This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This gives you plenty of time to catch up on any sessions you missed, revisit important topics, and complete your CME requirements. How Do I Claim CME Credit? Claiming your CME credit is simple. Congratulations on earning your CME credits—well done! How Do I Access CMHC On-Demand? Getting started is easy.
Competence in selecting treatments for long-term obesity management rose from 43% pre-test to 95% post-test. Neha Agarwal, PhD, Clinical Director at Cardiometabolic Health Congress , Informa Connect, recently presented significant findings at the 84th American Diabetes Association (ADA) Scientific Sessions.
Singh, MBBS, FRCP, MBA Advances in Obesity Pharmacotherapy Louis J. CME-Supported Satellites and Sessions: Primetime CME Symposium Integrated Approach to Cardiorenal Management: Maximizing SGLT2 Inhibitor Benefits and Early Detection of HF and CKD Supported by an educational grant from BI-Lilly. Chair: Erin D.
The 19th Annual CMHC was more than just CME/CE medical education—it ignited global collaboration and inspired groundbreaking innovations. After the reception, many attendees enjoyed dinner at the PME (Non-CME) Dinner Symposium or ventured to one of Boston’s trendy Back Bay eateries. Experts like Louis J.
Black History Month is a poignant backdrop to the alarming rise in obesity and type 2 diabetes, particularly among those of marginalized populations. This troubling trend has cemented the 100-year reign of cardiovascular diseases (CVD) as the #1 killer in America.
As a leader in the field of research-based cardiometabolic health education, CMHC is proud to present its CME education outcomes study at ADA (American Diabetes Association) 2024 Scientific Sessions, which offers its education-focused agenda to a wide number of healthcare practitioners from all areas of the U.S.
A vast collection of webinars, CME activities, expert interviews, on-demand event recordings, news articles, drug pipelines, and many other resources are now grouped into areas of specialty focus. For instance, a pediatric provider may be only interested in topics pertaining to childhood obesity.
SUMMIT Trial : Weekly subcutaneous tirzepatide showed significant reductions in CV death and HF-related events among patients with HFpEF and obesity. Earn 14 CME credits anytime on any device. Read the published study. Access the full study. View the study. Co-chaired by leading experts Peter Libby, MD , Erin D.
Innovations in Cardiorenal Metabolic Medicine The event will focus on the whole spectrum of cardiorenal metabolic disease, including obesity, diabetes, lipids, hypertension, and cardiorenal disease. The robust conference agenda begins with FDA updates and advancements in cardiorenal metabolic care.
cardiometabolic health CME/CE conference: the 19th Annual CMHC. 42% of adults are considered obese , increasing their risk of diabetes, hypertension, and cardiovascular issues. 4 Advances in Obesity Pharmacotherapy Session: “Advances in Obesity Pharmacotherapy” Presenter: Louis J. In the U.S.,
This patient’s case presents a common and challenging scenario in primary care and endocrinology, where T2D, obesity, and metabolic dysfunction intersect with liver disease. Case Study: A Common Clinical Scenario This case study highlights the complex relationship between metabolic disease and liver health.
Healthcare professionals should consider pharmacotherapy options that address T2D, obesity, and liver disease: Statins : Statins are first-line therapies for managing dyslipidemia and reducing cardiovascular risk in patients with MASH. This dual action makes tirzepatide a promising option for treating MASH in patients with T2D and obesity.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content